<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="jcm-09-02084-t002" orientation="portrait" position="float">
 <object-id pub-id-type="pii">jcm-09-02084-t002_Table 2</object-id>
 <label>Table 2</label>
 <caption>
  <p>Brief description of COVID-19 therapeutic options recommended by World Health Organization (WHO) guidelines [
   <xref rid="B117-jcm-09-02084" ref-type="bibr">117</xref>,
   <xref rid="B118-jcm-09-02084" ref-type="bibr">118</xref>,
   <xref rid="B119-jcm-09-02084" ref-type="bibr">119</xref>,
   <xref rid="B120-jcm-09-02084" ref-type="bibr">120</xref>].
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Name</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pharmacological Class</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Phase </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EC
     <sub>50</sub> (half maximal effective concentration)
    </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Action</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adverse Effects</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Remdesivir—(RDV)</bold>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nucleoside analogue</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Severe </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.77 µM </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200 mg—day 1; 100 mg/day—9 days</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">inhibitor of the CoVs RNA-dependent RNA polymerase (RdRp)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>incompletely characterized toxicological profile: phlebitis, constipation, headache, ecchymosis, nausea, pain in the extremities</p>
      </list-item>
      <list-item>
       <p>elevation of hepatic enzymes values</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Chloroquine (CQ)</bold>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4-aminoquinoline</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild-to-moderate and severe—depending on the guideline applied </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.90 µM (24 h)
     <break/>5.47 µM (48 h)
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CQ base (600 mg/diagnosis; 300 mg—12 h later and 300 mg up to 5 days) or CQ phosphate (1000 mg/diagnosis; 500 mg—12 h later and 300 mg up to 5 days)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">weak base able to elevate the pH of acidic intracellular organelles, such as endosomes and lysosomes</td>
    <td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>retinopathy</p>
      </list-item>
      <list-item>
       <p>hypotension</p>
      </list-item>
      <list-item>
       <p>ECG changes</p>
      </list-item>
      <list-item>
       <p>irreversible cardiomyopathy—long-term users</p>
      </list-item>
      <list-item>
       <p>direct myocardial toxicity</p>
      </list-item>
      <list-item>
       <p>exacerbate the existent myocardial dysfunction</p>
      </list-item>
      <list-item>
       <p>QT prolongation</p>
      </list-item>
      <list-item>
       <p>risk of Torsade de Pointes (TdP) even at therapeutic doses</p>
      </list-item>
      <list-item>
       <p>interaction with antiarrhythmics</p>
      </list-item>
     </list>* in the case of HCQ, the adverse effects have a lower intensity, but are not absent
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Hydroxychloroquine (HCQ)</bold>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4-aminoquinoline</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild-to-moderate and severe—depending on the guideline applied</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.14 µM (24 h)
     <break/>0.72 µM (48 h)
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCQ—400 mg at suspicion/diagnosis; 400 mg—12 h later and 200 mg—until day 5</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">weak bases able to elevate the pH of acidic intracellular organelles, such as endosomes and lysosomes</td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Liponavir/ritonavir (LPv/r)</bold>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protease inhibitor</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild-to-moderate</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">400 mg/100 mg/day—14 days</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peptidomimetic inhibitor of HIV protease enzyme</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>hypercholesterolemia and increased serum triglycerides</p>
      </list-item>
      <list-item>
       <p>increased gamma-glutamyl transferase</p>
      </list-item>
      <list-item>
       <p>increased serum ALT</p>
      </list-item>
      <list-item>
       <p>upper respiratory tract infection</p>
      </list-item>
      <list-item>
       <p>diarrhea</p>
      </list-item>
      <list-item>
       <p>nausea</p>
      </list-item>
      <list-item>
       <p>headache</p>
      </list-item>
      <list-item>
       <p>skin rush</p>
      </list-item>
      <list-item>
       <p>neutropenia</p>
      </list-item>
      <list-item>
       <p>anxiety</p>
      </list-item>
      <list-item>
       <p>QT prolongation</p>
      </list-item>
     </list>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
